Compare AENT & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AENT | CDXS |
|---|---|---|
| Founded | 1990 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Durable Goods | Major Chemicals |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 303.3M | 256.3M |
| IPO Year | 2020 | 2008 |
| Metric | AENT | CDXS |
|---|---|---|
| Price | $5.62 | $1.67 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | 10.4K | ★ 1.6M |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 233.33 | 43.82 |
| EPS | ★ 0.32 | N/A |
| Revenue | $2,700,000.00 | ★ $138,590,000.00 |
| Revenue This Year | $3.44 | $7.73 |
| Revenue Next Year | $1.64 | $14.24 |
| P/E Ratio | $17.47 | ★ N/A |
| Revenue Growth | N/A | ★ 32.30 |
| 52 Week Low | $4.36 | $0.96 |
| 52 Week High | $8.80 | $2.98 |
| Indicator | AENT | CDXS |
|---|---|---|
| Relative Strength Index (RSI) | 47.38 | 47.41 |
| Support Level | $5.59 | $1.57 |
| Resistance Level | $6.25 | $1.75 |
| Average True Range (ATR) | 0.35 | 0.09 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 46.74 | 87.93 |
Alliance Entertainment Holding Corp is a distributor of music, movies, and consumer electronics. It offers products consisting of vinyl records, compact discs, DVDs, Blu-rays, and video games. The company serves customers of every size, providing a suite of services to resellers and retailers around the world. The company has two divisions: Alliance Home Entertainment, which offers full-service support across production, marketing, and retail execution. and Alliance Authentic, which focuses on licensed collectibles and branded merchandise, including partnerships with Handmade by Robots, Master Replicas, and Weta Workshop.
Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.